

Published in final edited form as:

Biochem Pharmacol. 2008 August 15; 76(4): 482–494. doi:10.1016/j.bcp.2008.05.032.

The A₃ Adenosine Receptor Agonist CF502 Inhibits the PI3K, PKB/Akt and NF-κB Signaling Pathway in Synoviocytes from Rheumatoid Arthritis Patients and in Adjuvant Induced Arthritis Rats

A. Ochaion^{1,2}, S. Bar-Yehuda¹, S. Cohen¹, H. Amital³, K.A. Jacobson⁴, B.V. Joshi⁴, Z.G. Gao⁴, F. Barer¹, R. Patoka¹, L. Del Valle⁵, G. Perez-Liz⁵, and P. Fishman¹

¹Can-Fite BioPharma Ltd., Kiryat-Matalon, Petah -Tikva, 49170, Israel

²Bar Ilan University, The Mina and Everard Goodman Faculty of Life Sciences, Ramat Gan, Israel

³Internal Department D, Meir Medical Center, Kfar Saba, Israel

⁴National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA

⁵Department of Neuroscience, Neuropathology Core & Center for NeuroVirology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA

Abstract

The A₃ adenosine receptor (A₃AR) is over-expressed in inflammatory cells and was defined as a target to combat inflammation. Synthetic agonists to this receptor, such as IB-MECA and CI-IB-MECA, exert an anti-inflammatory effect in experimental animal models of adjuvant and collagen induced arthritis.

In this study we present a novel A₃AR agonist, CF502, with high affinity and selectivity at the human A₃AR. CF502 induced a dose dependent inhibitory effect on the proliferation of fibroblast-like synoviocytes (FLS) via de-regulation of the nuclear factor-kappa B (NF-κB) signaling pathway. Furthermore, CF502 markedly suppressed the clinical and pathological manifestations of Adjuvant Induced Arthritis (AIA) in a rat experimental model when given orally at a low dose (100 μg/kg). As is typical of other G-protein coupled receptors, the A₃AR expression level was down-regulated shortly after treatment with agonist CF502 in paw and in peripheral blood mononuclear cells (PBMCs) derived from treated AIA animals. Subsequently, a decrease in the expression levels of Protein Kinase B/Akt (PKB/Akt), IκB kinase (IKK), (I kappa B) IκB, NF-κB and tumor necrosis factor-alpha (TNF-α) took place. In addition, the expression levels of Glycogen synthase kinase-3 beta (GSK-3β), β-catenin, and Poly (ADP-ribose) polymerase (PARP), known to control the level and activity of NF-κB, were down-regulated upon treatment with CF502.

Taken together, CF502 inhibits FLS growth and the inflammatory manifestations of arthritis, supporting the development of A₃AR agonists for the treatment of rheumatoid arthritis.

Keywords

A₃ adenosine receptor; CF502; rheumatoid arthritis; PKB/Akt; NF-κB; TNF-α

1. Introduction

The A₃ adenosine receptor (A₃AR) belongs to the family of the Gi-protein associated cell membrane receptors. Considerable evidence has been accumulated indicating that activation of the A₃AR results in an anti-inflammatory effect. The A₃AR was found to be highly expressed in inflammatory tissues, such as synovia and paw derived from an adjuvant-induced arthritis (AIA) model in rats, whereas low expression was found in relevant tissues from naïve animals. Interestingly, receptor up-regulation was also mirrored in the peripheral blood mononuclear cell (PBMCs) of the AIA rats reflecting receptor status in the inflamed tissue. Moreover, A₃AR up-regulation was found in PBMCs from rheumatoid arthritis (RA) patients compared to low levels in PBMCs from healthy subjects. Receptor over-expression was found to be a result of high TNF- α levels in the cell microenvironment, known to induce up-regulation of the transcription factor NF- κ B. DNA binding sites to NF- κ B are present in the promoter of the A₃AR gene affecting its transcription. As is typical of other Gi coupled protein receptors, A₃AR expression levels were found to be down-regulated upon activation with a specific agonist, such as CF101 (*N*⁶-(3-iodobenzyl)adenosine-5'-*N*-methyluronamide, IB-MECA). This was noted both in the inflammatory tissues and in PBMCs, most likely due to receptor internalization and degradation (1-4).

Earlier studies showed that oral treatment of AIA rats with CF101 resulted in amelioration of the pathological and clinical disease manifestations, as well as prevention of bone destruction and cartilage damage. The mechanism of action involved with the anti-inflammatory effect of CF101 entails down-regulation of the PKB/AKT - NF- κ B signaling pathway resulting in decreased levels of TNF- α , prevention of osteoclasts formation and induction of inflammatory cell apoptosis (1-3). CF101 was also found to be safe and well tolerated in Phase I/Phase IIa clinical studies and was able to improve indicators and symptoms of RA (5,6).

In addition to the anti-inflammatory effect, A₃AR agonists are known to be effective in protecting against lung and myocardial ischemia/reperfusion injury, colitis, sepsis-induced mortality, ischemic brain injury as well as protecting the myeloid system against chemotherapeutic damage. All the aforementioned studies were carried out utilizing either of the two prototypical A₃AR agonists, IB-MECA or its 2-chloro analogue Cl-IB-MECA. Both agonists possess high affinity and selectivity for the A₃AR and are known to have high oral bioavailability (5,7-11).

Recently, a novel A₃AR agonist, CF502 (generically known as MRS3558) [(1'R,2'R,3'S,4'R,5'S)-4- {2-chloro-6-[(3-chlorophenylmethyl)amino]purin-9-yl}-1-(methylaminocarbonyl) bicyclo [3.1.0]hexane-2,3-diol], was synthesized at the National Institutes of Health and displayed enhanced selectivity and specificity for the human A₃AR (12). This agonist belongs to the class of (N)-methanocarba nucleosides, in which the ribose ring was substituted by an (N)-methanocarba ring system (Figure 1), resulting in enhancement of the agonist affinity to the A₃AR. Full agonism of MRS3558 in activating the A₃AR was dependent on the presence of the 5'-N-methyluronamido moiety. Therefore, MRS3558 is at least 1000-fold selective for the human A₃AR compared to A₁, A_{2A}, and A_{2B} AR subtypes (13,14).

MRS3558 was tested earlier by Matot et al. for its *in vivo* activity. It was found that administration of the drug before reperfusion attenuated lung injury in cats. MRS3558 also protected the alveoli from apoptosis. Administration of an A₃AR antagonist (MRS1191) completely abolished the protection of the lungs induced by MRS3558, demonstrating the specific activation of the A₃AR by the agonist. The mechanism of action suggested by the authors includes up-regulation of the ERK pathway (14).

In this study we demonstrate the anti-inflammatory effect of CF502 on human FLS primary cultures as well as in an AIA model. Treatment with CF502 exerted a potent dose dependent anti-inflammatory effect both *in vivo* and *in vitro*, via a mechanism that includes down-regulation of the PKB/Akt -NF- κ B signal transduction pathway.

2. Materials and Methods

2.1 Reagents

The A₃AR agonist, [(1'R,2'R,3'S,4'R,5'S)-4-{2-chloro-6-[(3-chlorophenylmethyl)amino]purin-9-yl}-1-(methylaminocarbonyl)bicyclo[3.1.0]hexane-2,3-diol], designated CF502, was synthesized at the Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (Bethesda, MD, USA). A stock solution of 10 mM was prepared in DMSO and further diluted in PBS or in culture medium.

Rabbit polyclonal antibodies against rat or human A₃AR and the signaling proteins PI3K (catalytic subunit), phosphorylated (at serine 473) and non phosphorylated PKB/Akt, IKK α / β , p65 or p50 subunit of the NF- κ B, TNF- α , phosphorylated and total GSK-3 β , β -catenin and PARP were purchased from (Santa Cruz, CA, USA).

2.2 Binding assay

For human or rat A₃AR binding experiments, the procedures used were similar to those previously described (12). Briefly, each tube contained 100 μ l of membrane suspension, 50 μ l of [¹²⁵I]I-AB-MECA ([¹²⁵I]N⁶-(4-amino-3-iodobenzyl)adenosine-5'-N-methyluronamide, final concentration 0.5 nM), and 50 μ l of increasing concentrations of compounds in Tris-HCl buffer (50 mM, pH 7.4) containing 10 mM MgCl₂, 1 mM EDTA. Nonspecific binding was determined using 10 μ M Cl-IB-MECA. The mixtures were incubated at 25°C for 60 min. Binding reactions were terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester (Brandell, Gaithersburg, MD). Filters were washed three times with ice-cold buffer. Radioactivity was determined in a Beckman 5500B γ -counter. The binding of [³H]CCPA ([³H]2-chloro-N⁶-cyclopentyladenosine, final concentration 0.5 nM) to recombinant human A₁ARs or native rat A ARs from rat cerebral cortex and the binding of [³H]CGS21680 ([³H]2-[p-(2-carboxyethyl)phenyl-ethylamino]-5'-N-ethylcarboxamidoadenosine, final concentration 5.0 nM) to recombinant human A_{2A}ARs or native rat A_{2A}ARs from rat striatum were performed as previously described (12). Binding and functional parameters were calculated using Prism 4.0 software (GraphPAD, San Diego, CA, USA). IC₅₀ values obtained from competition curves were converted to K_i values using the Cheng-Prusoff equation (15). Data were expressed as mean \pm standard error.

2.3 Cyclic AMP accumulation assay

CHO (Chinese hamster ovary) cells expressing the recombinant human A₃AR or A_{2B} receptors were cultured in Dulbecco-modified Eagle's medium (DMEM) and F12 (1:1) supplemented with 10% fetal bovine serum, 100 Units/ml penicillin, 100 μ g/ml streptomycin and 2 μ mol/ml glutamine. Cells were plated in 24-well plates in 0.5 ml of medium. After 24 h, the medium was removed and cells were washed three times with 1 ml DMEM, containing 50 mM N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid (HEPES), pH 7.4. Cells were then treated with agonists in the presence of rolipram (10 μ M) and adenosine deaminase (3 Units/ml). After 45 min forskolin (10 μ M) was added to the medium, and incubation was continued an additional 15 min. For the assay of the A_{2B} receptor assay, agonists were incubated for 30 min under the same conditions. The reaction was terminated upon removal of the supernatant, and cells were lysed following the addition of 200 μ l of 0.1 M ice-cold HCl. The cell lysate was resuspended and stored at -20°C. For determination of cyclic AMP production, the method of Nordstedt

and Fredholm was used (16). Protein kinase A (PKA) was incubated with ^3H]cyclic AMP (2 nM) in K_2HPO_4 /EDTA buffer (K_2HPO_4 , 150 mM; EDTA, 10 mM), 20 μl of the cell lysate, and 30 μl 0.1 M HCl or 50 μl of cyclic AMP solution (0-16 pmol/200 μL for standard curve). Bound radioactivity was separated by rapid filtration through Whatman GF/C filters and washed once with cold buffer. Bound radioactivity was measured by liquid scintillation spectrometry.

2.4 Human synovial cell cultures

Protocols for this study were approved by the hospitals' ethical committees. Synovial fluid samples were collected from RA patients after an informed consent was signed. The cells were enzymatically dissociated in a mixture of type I collagenase (4 mg/ml) and 0.25 w/v trypsin in DMEM for 4 h at 37°C. After centrifugation for 10 min at 500Xg, the cells were resuspended and cultured in DMEM containing 15% FCS, 2mM glutamine, 100 U/ml penicillin, 100 $\mu\text{g}/\text{ml}$ streptomycin in a 37°C, 5% CO_2 incubator. After overnight incubation the non-adherent cells were removed. The adherent cells (FLS) were sub-cultured at a 1:2 ratio, and the cells from passages 3-5 were used in the experiments. The cells were designated as RA FLS.

2.5 FLS proliferation assay

^3H]Thymidine incorporation assay was used to evaluate the effect of CF502 on human RA FLS growth. The cells were serum starved overnight and then were incubated (2.5×10^4 cells/ml) with CF502 (0.1, 1, 10, 100 nM), in 96-well plates for 48 h. The selective A_3AR antagonist MRS 1191 (1,4-dihydro-2-methyl-6-phenyl-4-(phenylethynyl)-3,5-pyridinedicarboxylic acid, 3-ethyl 5-(phenylmethyl) ester) (Sigman RBI, Natick, MA, USA) was added at a concentration of 10 nM to the cell cultures 30 min prior to the introduction of CF502. TNF- α was added to the culture system at a dose of 0.5 ng/ml.

2.6 Experimental AIA model

Female Lewis rats, aged 8-12 weeks were obtained from Harlan Laboratories (Jerusalem, Israel). Rats were maintained on a standardized pelleted diet and supplied with tap water. Experiments were performed in accordance with the guidelines established by the Institutional Animal Care and Use Committee at Can-Fite BioPharma, Petach Tikva, Israel. The rats were injected subcutaneously (SC) at the tail base with 100 μl of a suspension composed of incomplete Freund's adjuvant (IFA) (Sigman RBI, Natick, MA, USA) with 10 mg/ml heat killed *Mycobacterium tuberculosis*, (Mt) H37Ra, (Difco, Detroit, USA). Each group contained 10 animals and the study was repeated three times.

CF502 treatment was initiated on day 14 after vaccination when the clinical arthritis became apparent. CF502 (at a dose of 1, 10 and 100 $\mu\text{g}/\text{kg}$) was orally administered by gavage. The animals were treated thrice daily in accordance with our former experience with another A_3AR agonist (IB-MECA designated as CF101) used in the same AIA model (un published data). The control group received vehicle only. The treatment lasted throughout the remaining days of the experiment.

The clinical disease activity score was assessed as follows: the animals were inspected every second day for symptoms of clinical arthritis. The scoring for each limb ranged from 0 - 4: 0 - no arthritis; 1 - redness or swelling of one toe/finger joint; 2 - redness and swelling of more than one toe/finger joints, 3 - involvement of the ankle and tarsal-metatarsal joints involvement. 4 - redness or swelling of the entire paw. The clinical score was calculated by adding the scores for four individual legs.

The histological score was assessed as follows: Animals were sacrificed on day 28. The legs were removed up to the knee level, fixed in 10% formaldehyde, decalcified, dehydrated, paraffin-embedded, cut into 4 μm sections, and stained using hematoxylin-eosin.

The assessment of all pathological findings were performed using a semi-quantitative grading scale of 0 to 4 for the following parameters: the extent of infiltration of inflammatory cells to the joint tissues; synovial lining cell hyperplasia; pannus formation; destruction of joint cartilage layers. Bone damage and erosion score was graded from 0 to 5: 0 - normal; 1 - minimal loss of cortical bone at a few sites; 2 - mild loss of cortical trabecular bone; 3 - moderate loss of bone at many sites; 4 - marked loss of bone at many sites; 5 - marked loss of bone at many sites with fragmenting and full thickness penetration of inflammatory process or pannus into the cortical bone. The mean of all the histological parameter scores were designated "Histology Score".

2.7 Immuno-histochemical staining of paraffin embedded slides of paws tissues derived from AIA rats

The paraffin of the slides was melted from the sections by immersing them in xylene, 3 times for 30 min each. The tissues were hydrated with serial dilutions of ethanol followed by retrieval of antigen upon heating with citrate buffer at 95°C for 30 min. The slides were allowed to cool down and then washed 3 times in PBS. Endogenous peroxidase quenching was performed by washing the sections with fresh 20% hydrogen peroxide in methanol for 20 min. The sections were then blocked by incubating in 5% normal goat serum in PBS-BSA 0.1% for 2 h.

The primary antibody (Novus Biologicals, Inc; Littleton, CO) was diluted in 0.1% PBS-BSA and incubated overnight with the sections at room temperature. After 3 times washing in 1x PBS the slides were incubated in 0.5% biotinylated secondary antibody in PBS-BSA (0.1%) for 1 h at room temperature and then subjected to a avidin-biotin complexation (ABC) After another wash the slides were incubated with DAB substrate, which was removed by washing in tap water and inactivated with bleach. A light hematoxylin counter-staining was performed, the hematoxylin was then removed by a rapid dip in acidic alcohol, and the slides were then exposed to Re-blue in ammonium hydroxide, dehydrated, and mounted with Permount. PBMCs from naïve, AIA and MRS3558-treated rats were fractionated from heparinized blood using a Ficoll-Hypaque gradient.

2.8 Protein Extract preparation

The hind paws were dissected above the ankle joint. The bony tissue was broken into pieces, snap frozen in liquid nitrogen, and stored at -80°C until use. The paw tissues were added to (4 ml/g tissue) RIPA extraction buffer containing 150 mM NaCl, 1% NP40, 0.5% deoxycholate, and 0.1% SDS, 50 mM Tris (pH - 7.4). Tissues were homogenized on ice with a Polytron and centrifuged, and the supernatants were subjected to Western Blot (WB) analysis.

Blood samples were withdrawn from the heart of anesthetized rats and subjected to a Ficoll Hypaque gradient. The PBMCs were then washed with PBS and stored at -80°C until use.

FLS cells were removed from the flasks by trypsinization, washed with PBS and stored at -80°C until use.

Samples were rinsed with ice-cold PBS and transferred to ice-cold RIPA buffer. Cell debris was removed by centrifugation for 10 min, at 7500Xg. Protein concentrations were determined using the Bio-Rad protein assay dye reagent.

2.9 Western blot analysis of A₃AR and additional signaling proteins

WB analysis was carried out according to the following protocol. Equal amounts of protein (50 µg) were separated by SDS-PAGE, using 10% polyacrylamide gels (Invitrogen). The resolved proteins were then electroblotted onto nitrocellulose membranes (Schleicher & Schuell, Keene, NH, USA). Membranes were blocked with 3% non-fat milk and incubated with the desired primary antibody (dilution 1:1000) for 24 h at 4°C. Blots were then washed and incubated with a secondary antibody (0.1% non-fat milk) for 1 h at room temperature. Bands were recorded using BCIP/NBT color development kit (Promega, Madison, WI, USA). WBs were normalized against the housekeeping protein, β-actin. The optical density of the bands was quantified using an image analysis system and corrected by the optical density of the corresponding β-actin bands. The control values were designated as 1 unit. Data presented in the different figures are representative of at least four different experiments.

2.10 Preparation of nuclear extracts

Nuclear extract proteins from human FLS cultures treated and un-treated with MRS3558 were prepared by incubating the cells for 15 min on ice in a buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT), and 0.5 mM phenylmethylsulfonylfluoride (PMSF). Following incubation, Nonident P-40 (10%) was added, cells were vortexed for 10 s and centrifuged. The pellet was re-suspended in a buffer containing 20 mM HEPES (pH = 7.9), 400 mM NaCl, 1 mM EDTA, 1 mM DTT and 1 mM PMSF, rocked on a shaker for 15 min at 41° C and centrifuged. Protein was quantified utilizing Bio-Rad protein assay dye reagent

2.11 Gel shift assay

Nuclear protein extracts from FLS treated and un-treated with CF502 were quantified and subjected to Gel shift assay. Double stranded oligonucleotide for the consensus sequence for NF-κB were end-labeled with [γ -³²P]ATP (Amersham) using polynucleotide kinase (Promega). Protein extracts that were prepared from nuclear fraction (10µg) and incubated for 30 min at room temperature with the end-labeled double-stranded oligonucleotides containing the NF-κB site (15,000 cpm each) in binding buffer containing 5 mM MgCl₂, 250 mM NaCl, 2.5mM DTT, 25mM EDTA, 20% glycerol, 50mM Tris-HCl pH 7.5 and 2µg/sample of ploy (dI)*poly(dC) in a final volume of 25µl. Competition with unlabeled oligonucleotide of NF-κB binding sequence at a 100-fold molar excess was used to analyze specific bands .

The sequence of the oligonucleotide was as follows: NF-κB, 5-' AGTTGAGGGGACTTTCCAGGC-3'. It contained the consensus NF-κB binding site in the IgL chain enhancer. The reaction product was analyzed by 6% non-denaturing polyacrylamide gel electrophoresis. The specific bands were visualized by X-ray autoradiography.

2.12 Statistical analysis

The data of the *in vitro* proliferation assays represent a sum of three different assays in which each sample was repeated thrice. The western blots presented are derived from a representative study and the results shown are similar to results derived from other studies. The *in vivo* data present a sum of 4 different studies in which each group included between 7-10 animals.

The results were evaluated using the Student's t-test, with statistical significance set at p<0.05. Comparison between the mean values of different experiments was carried out. All data are reported as mean ± SD.

3. Results

3.1 Binding affinity and agonist efficacy of CF502

The multi-step synthesis of the (N)-methocarpa nucleoside CF502 was carried out as reported, and the binding affinities at the ARs were evaluated as previously described (12). We have expanded upon the previous pharmacological characterization of CF502. The K_i values at the human A_1 , A_{2A} , A_{2B} and A_3 ARs are $260 \pm 60(12)$, $2300 \pm 100(12)$, and 0.29 ± 0.04 nM, respectively. The EC_{50} value of CF502 to stimulate adenylyl cyclase in CHO cells expressing the human A_{2B} AR was $11.4 \mu\text{M}$. The binding affinity (K_i) at the rat A_1 , A_{2A} , and A_3 ARs are 105 ± 20 , 1080 ± 180 , and $1.0 \pm 0.1(12)$ nM, respectively.

CF502 was further evaluated in a cyclic AMP functional assay in intact CHO cells stably expressing the human A_3 AR. Figure 2 shows that both CF502 and Cl-IB-MECA were fully efficacious, but CF502 was more potent as an A_3 AR agonist. The EC_{50} values in the A_3 AR-mediated inhibition of forskolin-stimulated adenylyl cyclase by CF502 and Cl-IB-MECA were 0.38 ± 0.12 and 1.4 ± 0.3 nM, respectively. The EC_{50} value of CF502 to stimulate adenylyl cyclase in CHO cells expressing the human A_{2B} AR was $11.4 \mu\text{M}$

3.2 Effect of CF502 on human FLS

FLS were cultured from synovial fluids derived from RA patients. The cultures were incubated in the presence of various CF502 concentrations (0.1 nM-100 nM). An ^3H thymidine incorporation assay was utilized to evaluate the effect of CF502 on FLS proliferation. CF502 exerted a concentration-dependent inhibitory effect on the cell proliferation (Figure 3a). Administration of MRS 1191 (10 nM), an A_3 AR antagonist, counteracted the inhibitory effect of CF502, demonstrating the specificity of the response (Figure 3b). Incubation of RA FLS in the presence of TNF- α (0.5 ng/ml), a pro-inflammatory cytokine, increased the cell proliferation rate by $28 \pm 8.9\%$. Administration of CF502 (10 nM) to this culture resulted in a $60 \pm 3\%$ inhibition of cell proliferation (Figure 3c).

Upon treatment of the FLS with 10 nM of CF502 A_3 AR expression level was down-regulated (Figure 4a) This was followed by decreased expression level of the catalytic subunit of PI3K and of the phosphorylated form of PKB/Akt, while the non phosphorylated PKB/Akt remained un-changed. These results demonstrate that not only the expression levels of these signal proteins were decreased, their activity was also down-regulated. The expression levels of the down-stream signal proteins IKK α/β and NF- κ B (p65) also decreased in the FLS upon treatment with 10 nM CF502 (Figure 4b & 4c). We further looked at the activity of NF- κ B in CF502-treated FLS nuclei utilizing a band shift assay. Reduced DNA binding activity was noted (Figure 4c). In addition the expression of phosphorylated GSK-3 β known to control the activity of NF- κ B was decreased upon treatment with CF502, while the level of the total GSK-3 β remained un changed (Figure 4d),

3.3 CF502 ameliorated the clinical and pathological manifestations of AIA

Oral treatment with CF502 (1, 10, and 100 $\mu\text{g}/\text{kg}$, thrice daily) was initiated upon onset of disease and lasted till study termination. A statistically significant (which was noted starting day 18-20 after disease induction, $p < 0.05$) dose-dependent decrease in the severity of the disease, with the maximal anti-inflammatory effect at 100 $\mu\text{g}/\text{kg}$, was noted. Figure 5 presents the clinical scores of the disease upon treatment with the various CF502 doses during course of the study.

In addition, pathological and histological evaluation, as well as analysis of key signaling proteins downstream to the A_3 AR activation were conducted in paw and PBMCs from AIA animals receiving a dose of 100 $\mu\text{g}/\text{kg}$ CF502. Histological evaluation of Hematoxylin & Eosin

stained slides from vehicle- and CF502-treated animals revealed signs of severe arthritis in the control animals. The arthritis was characterized by a robust inflammatory reaction that included response of lymphocytes and eosinophils, hyperplasia of synovial cells, moderate to severe fibrosis, pannus formation, and extensive cartilage destruction and bone lysis, which was accompanied by the presence of hyperplastic osteoclasts. Treatment with CF502 resulted in a significant suppression of these histopathological changes. Minimal inflammatory cells were found in CF502-treated animals, however granulation tissue remained in the synovia, suggesting that a transient inflammatory reaction was present in the past. The synovial membrane was not fibrotic and presented normal synoviocytes. The cartilage and bone were well preserved and very few osteoclasts were found (Figure 6).

3.4 Analysis of A₃AR protein expression levels and down-stream signaling proteins involved with the anti-inflammatory activity of CF502

3.4.1. Analysis of paw extracts—A₃AR protein expression levels were down-regulated in paw extracts derived from the CF502-treated AIA rats in comparison to vehicle-treated animals (Figure 7a). These data were supported by immuno-histochemical analysis of joint sections showing pronounced receptor exhibition in virtually all the inflammatory cells in the control group whereas A₃AR exhibition was found only in a very few inflammatory cells remaining in the CF502-treated group. In addition, hyperplastic synovial cells in the control group highly expressed A₃AR, compared with the CF502-treated group, in which only weak expression in a single layer of thin synoviocytes was found (Figure 7b).

WB analysis of the paw extracts revealed a decrease in the protein expression levels of PI3K, PKB/AKT, IKK, NF-κB (p65) and TNF-α (Figure 8).

Further analysis showed that the levels of GSK-3β, β-catenin and PARP, known to control the expression and activity of NF-κB, were decreased upon treatment with CF502 (Figure 9a, 9b & 9c).

3.4.2.. Analysis of PBMCs—A marked reduction in the A₃AR expression levels was noted in PBMCs derived from the CF502-treated group in comparison to vehicle-treated animals (Figure 10a). This was directly correlated to a reduction in the expression level of NF-κB (p50), known to act as a transcription factor of A₃AR (Figure 10b).

4. Discussion

The major finding of the present study is the dose-dependent anti-inflammatory effect of CF502 on human FLS derived from RA patients. In addition, CF502 treatment reduced the clinical and pathological manifestations of arthritis in an *in vivo* experimental model of AIA. Mechanistically, CF502 de-regulated the NF-κB signaling pathway via the modulation of various intermediate signaling proteins.

Our previous studies as well as studies by others demonstrate that A₃AR activation plays an important role in attenuating anti-inflammatory responses (1-4,17-23). The data produced in this study further support these findings utilizing a novel synthetic agonist with a profile different from those of previously used agonists.

CF502 possesses a K_i value of 0.3 nM at the human A₃AR (K_i of 0.2 nM), which is several-fold higher affinity than that reported earlier for IB-MECA (22). At the same time, CF502 has a lower affinity than IB-MECA at the A_{2A}AR, granting the molecule higher selectivity toward the human A₃AR. The functionality of the agonist was evidenced *in vitro* by the adenylyl cyclase response, which resulted in a decrease of forskolin-stimulated cyclic AMP accumulation.

The functionality of CF502 was tested by its anti-inflammatory effects in an *in vitro* (utilizing human RA FLS) and *in vivo* (in a rat AIA) systems. CF502 inhibited in a concentration-dependent manner the proliferation of the human FLS in the presence and absence of TNF- α . This effect was counteracted by an A₃AR antagonist, confirming that the drug induced the effect via receptor activation. CF502 inhibitory effect on the FLS proliferation might be due to cell cycle arrest or apoptosis. A point to note is the linear concentration-dependent inhibitory effect that was exerted by CF502. Former studies with other A₃AR agonists yielded a bell-shaped response rather than a linear one (22). This may be a result of the high affinity and selectivity of the CF502 to the human A₃AR.

In *in vivo* studies CF502 demonstrated a marked dose-dependent anti-inflammatory effect in the AIA rat model, manifested by marked improvement in the histology of the inflamed tissues. Interestingly, CF502 exerted a progressive dose-dependent anti-inflammatory response.

Shortly after treatment with CF502, A₃AR expression levels were down-regulated in the FLS as well as in paw and in PBMCs derived from AIA rats. This result was repeatedly shown in our previous studies with IB-MECA. The down-regulation of the receptor represents a response of the cells to the drug, manifested by receptor internalization and degradation. In this study, we first demonstrate this phenomenon, not only at the level of expression of signaling proteins, but also by immunohistochemistry, supporting our former findings that, typical of G_i-protein coupled receptors in general, A₃AR is down-regulated upon agonist treatment (24,25). Receptor down-regulation may also be a result of decreased NF- κ B levels upon treatment with CF502. Bioinformatic studies revealed the presence of NF- κ B in the A₃AR promoter supporting the role of this transcription factor in regulating A₃AR expression levels. Upon treatment with CF502, PI3K, PKB/Akt, IKK and I κ B were down-regulated, leading to decreased NF- κ B levels, which resulted in diminished A₃AR transcription and expression.

The de-regulation of the PKB/Akt-NF- κ B pathway attributes as well to the anti-inflammatory effect of CF502. Earlier studies showed that IB-MECA mediated the anti-inflammatory effect in the synovia, paw, lymph nodes and spleen via inhibition of the same pathway (1-3,23).

Similarly to IB-MECA, CF502 inhibited the protein expression level of PI3K, PKB/Akt, IKK and I κ B in the paw extracts derived from the treated AIA rats. These data support the concept that A₃AR activation generates downstream signal transduction pathways leading to NF- κ B inhibition.

NF- κ B expression level and activity can also be mediated by additional signaling proteins. The first is GSK-3 β , which is known to directly phosphorylate the p65 NF- κ B subunit at Ser468 or Ser536. In addition, GSK-3 β reduces the activation of NF- κ B by preventing the association of the transcriptional co-activator CBP with p65. This in turn may result in a reduced formation of pro-inflammatory cytokines such as TNF- α and IL-6 (26-39). PARP-1 and β -catenin act as co-activators of NF- κ B and may regulate inflammation via their capability to control its transcriptional activity (30-33).

Taken together, CF502 exerts an anti-inflammatory effect via modulation of signaling proteins that control the NF- κ B pathway. It thus seems that NF- κ B is involved with the regulation of A₃AR expression level and functionality. CF502, an orally bio-available small molecule that is highly selective and possesses high affinity to the A₃AR, appears to be a potential drug candidate to control inflammation.

Abbreviations

AR, adenosine receptor.

5. References

1. Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, et al. The Anti-inflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. *Rheumatol* 2005;32:469–76.
2. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, et al. The PI3K-NF- κ B signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. *Art Res & Ther* 2006;8:1–9.
3. Rath-Wolfson L, Bar Yehuda S, Madi L, Ochaion A, Cohen S, Zabutti A, et al. IB-MECA, an A3 Adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. *Clin & Exp Rheumatology* 2006;24:400–6.
4. Madi L, Cohn S, Ochaion A, Bar-Yehuda S, Barer F, Fishman P. Over-expression of A3 Adenosine receptor in PBMC of rheumatoid arthritis patients: Involvement of NF- κ B in mediating receptor level. *J Rheumatology* 2007;34:20–6.
5. van Troostenburg AR, Clark EV, Carey WDH, Warrington SJ, Kerns WD, Cohn I, et al. Tolerability, pharmacokinetics, and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. *Int J Clin Pharmacol Ther* 2004;42:534–42. [PubMed: 15516022]
6. Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, et al. Clinical Evidence for Utilization of the A3 Adenosine Receptor as a Target to Treat Rheumatoid Arthritis: Data from a Phase II Clinical Trial. *J Rheumatology* 2008;35:1–7.
7. von Lubitz DK, Simpson KL, Lin RC. Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke. *Ann N Y Acad Sci* 2001;939:85–96. [PubMed: 11462807]
8. Bar-Yehuda S, Madi L, Barak D, Mittelman M, Ardon E, Ochaion A, et al. Agonists to the A₃ adenosine receptor induce G-CSF production via NF- κ B activation: a new class of myeloprotective agents. *Exp Hematol* 2002;30:1390–8. [PubMed: 12482500]
9. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, et al. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. *Am J Physiol Heart Circ Physiol* 2003;285:H2780–87. [PubMed: 12919933]
10. Rivo J, Zeira E, Galun E, Matot I. Activation of A3 adenosine receptor provides lung protection against ischemia-reperfusion injury associated with reduction in apoptosis. *Am J Transplant* 2004;4:1941–8. [PubMed: 15575895]
11. Lee HT, Kim M, Joo JD, Gallos G, Chen JF, Emala CW. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. *Am J Physiol Regul Integr Comp Physiol* 2006;291:R957–8. [PubMed: 16778064]
12. Tchilibon S, Joshi BV, Kim SK, Duong HT, Gao ZG, Jacobson KA. (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. *J Med Chem* 2005;48:1745–58. [PubMed: 15771421]
13. Joshi BV, Jacobson KA. Purine derivatives as ligands for A3 adenosine receptors. *Curr Top Med Chem* 2005;5:1275–95. [PubMed: 16305531]
14. Matot I, Weiniger CF, Zeira E, Galun E, Joshi BV, Jacobson KA. A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. *Crit Care* 2006;10:R65. [PubMed: 16623960]
15. Cheng Y, Prusoff W. Relationship between the inhibition constant (K₁) and the concentration of inhibitor which causes 50 per cent inhibition (I₅₀) of an enzymatic reaction. *Biochem Pharmacol* 1973;22:3099–3110. [PubMed: 4202581]
16. Nordstedt C, Fredholm BB. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. *Anal Biochem* 1990;189:231–4. [PubMed: 2177960]
17. Mabley J, Soriano F, Pacher P, Haskô G, Marton A, Wallace R, et al. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. *Eur J Pharmacol* 2003;466:323–9. [PubMed: 12694816]

18. Guzman J, Yu JG, Suntres Z, Bozarov A, Cooke H, Javed N, et al. ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. *Inflamm Bowel Dis* 2006;12:766–89. [PubMed: 16917233]
19. Lee JY, Jhun BS, Oh YT, Lee JH, Choe W, Baik HH, et al. Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. *Neurosci Lett* 2006;396:1–6. [PubMed: 16324785]
20. Martin L, Pingle SC, Hallam DM, Rybak LP, Ramkumar V. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. *J Pharmacol Exp Ther* 2006;316:71–8. [PubMed: 16188954]
21. Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L, et al. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. *Arthritis Res Ther* 2006;8:R169. [PubMed: 17101059]
22. Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. *Expert Opin Investig Drugs* 2007;16:1601–13.
23. Fishman, P.; Bar-Yehuda, S.; Madi, L. *Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases*. Haskó, G.; Cronstein, BN.; Szabo, C., editors. CRC Press; Boca Raton, FL: 2007. p. 299-312.
24. Schmid SL, Fuchs R, Male P, Mellman I. Two distinct subpopulations of endosomes involved in membrane recycling and transport to lysosomes. *Cell* 1988;52:73–83. [PubMed: 3345561]
25. Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A, Fishman P. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. *J Biol Chem* 2003;278:42121–30. [PubMed: 12865431]
26. Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K, et al. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. *J Biol Chem* 2004;279:49571–4. [PubMed: 15465828]
27. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. *Crit Care Med* 2005;33:1903–12. [PubMed: 16148458]
28. Ougolkov AV, Fernandez-Zapico E, Savoy D, Nrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. *Cancer Res* 2005;65:2076–81. [PubMed: 15781615]
29. Whittle BJ, Varga C, Posa A, Molnar A, Collin M, Thiemermann C. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. *Br J Pharmacol* 2006;147:575–82. [PubMed: 16314851]
30. Cho M, Gwak J, Park S, Won J, Kim DE, Yea SS, et al. Diclofenac attenuates Wnt/beta-catenin signaling in colon cancer cells by activation of NF-kappaB. *FEBS Lett* 2005;579:4213–4218. [PubMed: 16051228]
31. Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H, et al. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription. *J Biol Chem* 2005;280:40450–64. [PubMed: 16204234]
32. Sun J, Hobert ME, Duan Y, Rao AS, He TC, Chang EB, et al. Crosstalk between NF-kappaB and beta-catenin pathways in bacterial-colonized intestinal epithelial cells. *Am J Physiol. Gastrointest. Liver Physiol* 2005;289:G129–37. [PubMed: 15790758]
33. Espinoza LA, Tenzin F, Cecchi AO, Chen Z, Witten ML, Smulson ME. Expression of JP-8-induced inflammatory genes in AEII cells is mediated by NF-kappaB and PARP-1. *Am J Respir. Cell Mol Biol* 2006;35:479–87. [PubMed: 16690985]




Figure 1. Chemical structure of the synthetic A_3AR -selective agonist, CF502, used in this study. The bicyclic ring system (fused cyclopentane and cyclopropane rings) in place of the ribose moiety maintains a nucleoside conformation that is preferred in the A_3AR binding site (Tchilibon, et al., 2005).






Figure 2. Inhibition of forskolin-stimulated adenylyl cyclase in human A₃ARs expressed in CHO cells. Curves are representative of 3 separate determinations.

a.



b



c.






Figure 3. Effects of CF502 on the proliferation of FLS derived from human RA patients. The effect of CF502 on the proliferation of RA FLS was tested by ³[H]Thymidine incorporation assay. A) CF502 inhibited RA FLS proliferation by a dose dependent manner. B) CF502 inhibition effect was blocked by the administration of the A₃AR antagonist, MRS 1191 (10 nM), C) TNF-α (0.5 ng/ml) induced RA FLS proliferation was decreased by the administration of CF502 (10 nM) to the culture system.


a.



b.



c



d.




Figure 4.

Effect of CF502 on the expression levels of the A₃AR and down-stream key signaling proteins in FLS cultured from RA patients. Synovial cells RA patients were cultured *in vitro* in the presence of CF502 and then subjected to WB analysis. A) A₃AR expression level was down-regulated in the FLS upon treatment with 10 nM CF502. B) The expression levels of PI3K, phosphorylated PKB/Akt, IKK α / β were decreased in the FLS upon treatment with 10 nM CF502. C) Expression level and DNA binding activity of NF- κ B were down-regulated upon CF502 treatment. D) The expression level of phosphorylated GSK-3 β was decreased while the expression level the of total GSK-3 β was not affected by the CF502 treatment.




Figure 5. Effect of CF502 at various dosages on the clinical and pathological manifestations of AIA. Rats were immunized with a single injection of *Mycobacterium tuberculosis* in incomplete Freund's adjuvant. Treatment with CF502 was initiated upon the onset of arthritic disease.

CF502 was administered orally, thrice daily. Clinical score of the arthritic disease during course of the studies was evaluated. A significant dose-dependent decrease in the severity of the disease was noted, with a maximal inhibition at the dose of 100 $\mu\text{g}/\text{kg}$ of CF502 ($p < 0.05$).





Figure 6. Histological evaluation of the effect of CF502 on the inflammation, Fibrosis and destruction of cartilage and bone was observed in hematoxylin & eosin-stained slides in arthritic joints from AIA rats ($p < 0.05$). Treatment with CF502 resulted in a significant suppression of these histopathological changes.

a.



b.




Figure 7. Analysis of A₃AR protein expression levels and exhibition upon treatment with CF502 in AIA rats. A) A₃AR protein expression levels were down-regulated in paw extracts derived from CF502-treated AIA rats in comparison to vehicle-treated animals. B) Immuno-histochemical analysis of joint sections exhibited pronounced receptor expression in virtually all the inflammatory cells in the control group whereas A₃AR exhibition was found only in very few inflammatory cells remaining in the CF502-treated group.




Figure 8. Analysis of signaling proteins expression levels involved with the anti-inflammatory activity of CF502. WB analysis of the paw extracts revealed a decrease in the protein expression levels of PI3K, PKB/AKT, IKK, NF-κB and TNF-α upon treatment with CF502.






Figure 9. Effect of CF502 on the expression levels of signaling proteins controlling the expression and activity of NF- κ B. Protein extracts were prepared from the hind paws of CF502-treated and untreated AIA rats and subjected to WB analysis. The expression levels of A) GSK-3 β , B) β -catenin, and C) PARP were down-regulated.

a.



b.

**Figure 10.**

Analysis of the expression levels of the A₃AR and NF-κB in PBMCs derived from AIA rats. Protein extracts were prepared from the PBMCs of CF502-treated and untreated AIA rats and subjected to WB analysis. Marked reductions were noted in the expression level of: A) the A₃AR, and B) NF-κB, in PBMCs derived from the CF502-treated group in comparison to vehicle-treated animals.